BioData is conducting a 12 month study to examine the difference in the quality of life and effects on chronic pain levels of participating patients by using medical cannabis as an alternative to traditional opioid use. It's being called South Africa's first real world study of medical cannabis involving 1000 participants whose medical cannabis use will be observed over a period of time.

The trial is expected to provide much needed insight into the link between cannabis genetics and patient outcomes. In this episode of The Business of Health Gisele Wertheim Aymes speaks to Dr Shiksha Gallow the Medical Director of BioData about this ground breaking clinical trial.